We wish to inform you that the Board Meeting of the Company was held today i.e. on Wednesday, August 12, 2026 through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") with ....

August 12, 2026 To To The Manager, Listing Department The General Manager, Listing Department National Stock Exchange of India Ltd. BSE Limited Plot no. C/1 G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (East), Dalal Street, Mumbai- 400 051 Mumbai- 400 001 Symbol: BLISSGVS Scrip Code: 506197 Subject: Outcome of Board Meeting held on Wednesday, August 12, 2026 Dear Sir/Madam, We wish to inform you that the Board Meeting of the Company was held today i.e. on Wednesday, August 12, 2026, through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM"), with the deemed venue being the Registered Office of the Company. Pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the following matter amongst others: 1. The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. A copy of the unaudited standalone and consolidated financial results, along with the Limited Review Report of the Auditors, are enclosed below. 2. The draft of the Postal Ballot Notice seeking the approval of members of the Company for the appointment of Mr. Santosh Parab (DIN: 01622988) as a Director of the Company in the capacity of Non-Executive Non-Independent Director of the Company. The Board of Directors meeting commenced at 4:22 p.m. and concluded at 6:15 p.m. Kindly take the above information on record and acknowledge it. Thanking you. Yours faithfully, For Bliss GVS Pharma Limited Aditi Bhatt Company Secretary Encl: As above BLIGSVSPS H ARLMIAM ITED &P.s RegOdf.f -i01c2eH, y dPea rSka,k iRvoiahAdan,rd hEearsMitu -mbai-400072 CI-NL 24230MH1984PLC034771 StateomfUe nn-tA uSdtiatneddaa nlCdoo nnes olFiidnaatRneecdsi ufalolttr hsQ e u aretnedrJe udn3 e02 ,0 26 ""ILna kh Standalone Consolidated QuarEtnedre d YeaErn ded QuarEtnedre d YeaErn ded SrN.o. Particulars Jun3e0 2,0 26M ar3 12,0 26J un3e0 2,0 25M ar3 12,0 26J un3e02 ,0 26M ar3 12,0 26J un3e0 2,0 25 Ma3r1 2,0 26 Audited Audited Un-Audited Un-AuditAeudd iteUdn -Audited Un-AuditAeudd ited (ReNfaet7re) (ReNfoet7re) I RevefnruoOemp erations 22,158.2511, 153.1763, 336.7423, 980.2786, 557.2556, 699.2302, 746.9922, 711.28 II OthIenrc ome 876.16 930.181 ,059.247, 371.879 59.97 1,116.133, 545.407 ,352.98 Ill TotIanlc o(m1e+ 11) 23,034.2627, 083.1971, 395.7770, 352.2693, 517.2563, 815.2445, 292.13,20 0,064.26 IV Expenses a. CoosftM ateCroinaslusm ed 9,073.6130 ,227.781, 884.3863, 046.499, 463.6151 ,125.591, 341.2338 ,625.52 b. PurchoafSst eosc k-in-Trade 778.69 778.69 1,509.811, 821.122, 057.467, 125.24 C. ChanigInen sv enotfFoi rniieGssoh oedWdso ,r k-in-aPnSrdto ogicrTnker--sasd e 0.17 (1,264.(711,)7 20.(526,)5 61.6467)0 .99( 1,600.(823,)2 09.(525,)2 44.31) d. EmploByeeneeE fxiptesn se 3,656.636, 183.128, 810.1024, 149.748, 304.732, 613.831, 100.2163 ,642.75 e. FinaCnocset s 38.92 181.14 511.231 ,111.365 7.94 200.75 547.15 1,200.68 I. DeprecainaAdtm ioornt iEsxapteinosne s 903.03 784.15 768.463 ,101.959 93.75 867.07 820.13 3,348.34 g. OthEexrp enses 4,241.334, 814.039, 085.1339, 164.051, 168.366, 295.649, 324.5240 ,158.41 TotEaxlp enses 17,913.1775, 704.1245, 339.6339, 790.2612, 969.2222, 323.1172, 981.8203, 856.63 V Probfietf eoxrcee pIttieoamnnsatd la ( xI ll-IV) 5,120.942, 379.636, 056.1331, 562.071, 548.341, 492.363, 311.0199 ,207.63 VI LesEsx:c epIttieo(mnRsae Nlfo et5re) 35.82 (215.55) 2.66 (248.71) VII ProbfeiftTo ar(xeV -VI) 5,120.942, 415.438, 056.1331, 346.476, 548.341, 494.969, 311.0198 ,958.92 VIIIT aExx penses CurrTeanxt 958.09 1,099.614, 149.649, 142.419, 687.714, 976.410, 944.268, 807.23 DefeTrarxe d 330.02 67.58 (303.88()5 94.69)7 47.82( 1,188.1(11)7 4.53()1 ,433.12) Taxaatdijouns otfem aernyltei aeErrxs c ess(-)/Short(+) (28.96) 6.01 105.21 111.22 (24.45) 6.83 105.21 112.04 IX NePtr offotirht pe e riyoed{a/Vr I I-VIII) 3,861.737, 242.225, 105.299, 687.454, 137.230, 699.847, 436.1133 ,472.77 X OthCeorm prehIenncsoimvee iI.t etmhswa itnl olbt er e-cltaosP sriooffrLii oetsd s (iR)e measuorf(e lmoegsnastoi) fnD/ e fiBneendeP fliatn (86.34) 8.07 (12.73)( 24.00)( 86.34) 25.80 (12.73) (6.27) {iTiar)xe lattoii tnetgmh swa itnl olbt er eclatsoPs riofofirLie otds s 21.73 (2.99) 3.20 6.04 21.73 (7.45) 3.20 1.58 iiI.t etmhswa itbl erl e -cltaosP sriooffrLii oetsd s (iE)x chadnigfef eirtner nacnesstl hfaeit niansngtc aitaelom ffe onrteosip genr ations (153.33()4 15.30)7 94.77 207.89 {iTiar)xe lattoii tnetgmh swa itbl erl e clatsops riofofirlie otds s 156.84 (200.03) XI TotCaolm prehIenncsofimovtereh p ee riyoeda/r 3,797.136, 247.323, 095.796, 669.448, 919.236, 459.756, 021.3143 ,675.97 XII Proaftittr ibtuo:t able iO.w neorfts hC eo mpany 5,009.734, 557.541, 303.7192 ,912.92 iNio.n -ConItnrtoelrleisntgs 127.46 142.36 132.34 559.85 XIII OthCeorm prehIenncsoi{mvleeo/a s tst)r ibtuo:t able iO.w neorfts hC eo mpany (217.94()2 44.09)5 85.21 199.22 iNio.n -ConItnrtoelrleisntgs 3.98 3.98 XIV TotCaolm prehIenncsoaimtvete r ibtuo:t able iO.w neorfts hC eo mpany 4,791.830, 313.442, 889.0103 ,112.14 iNio.n -ConItnrtoelrleisntgs 127.46 146.34 132.34 563.83 xv Pauipde qusihtaycr aep ital 1,060.516, 057.819, 054.918, 057.819, 060.516, 057.819, 054.918, 057.89 (FaVcael u1e/�- ) XVI OthEeqru ity 1,14,460.93 1,18,232.07 XVII EarnPienSrgh saB raesa inDcdi lurtNeoAdtn nual(i!(s)e d) iB.a sic 3.65· 3.06· 2.00• 9.17 4_73• 3.37• 4.°0 8 12.23 iDii.l uted 3.ss• 2.99· 1.98* 9.00 4.65· 3.2a• 4.04· 12.00 cl .s.s Notes: 1 The above un-audited standalone and consolidated financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 12, 2026. These standalone and consolidated un audited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India. 2 The above un-audited standalone and consolidated financial results for the quarter ended June 30, 2026 are prepared in compliance with the Ind AS which have been subjected to a limited review by the statutory auditors of the Company. The statutory auditors have issued limited review reports with unmodified conclusion on the un-audited standalone and consolidated financial results. 3 As the Group's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed. 4 Employee Benefit Expenses includes Share Based Payment expense on account of ESOP Scheme, 2019 of~ 297.04 Lakh (quarter ended June 30, 2025 ~ 140.07 Lakh) as per Ind AS 102 "Share based Payment" for the quarter ended June 30, 2026. 5 Pursuant to the implementation of the New Labour Codes with effect from November 21, 2025, the Company and the Group had reassessed its employee benefit obligations and recognised an incremental expense of ~ 215.55 Lakh and ~ 248.71 Lakh in standalone and consolidated financials respectively for the year ended March 31, 2026, under Exceptional Items as past service cost. 6 During the quarter ended June 30, 2026, the Company has allotted 2,67,250 equity shares of~ 1 each fully paid, on exercise of stock options by employees in accordance with the Company's ESOP Scheme, 2019. The outstanding number of options as at June 30, 2026 are 22,36,250. 7 The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full financial year and the published year to date un-audited figures upto the third quarter of the previous financial year, which were subject to limited review. For BLISS GVS PHARMA LIMITED - -=' -.),. Narsimha Shibroor Karnath Place : Mumbai Managing Director [Showing first 8,000 characters — download PDF for full document]